Single nucleotide polymorphisms in glioma: from susceptibility loci to pharmacogenomic biomarkers

Gliomas are among the deadliest primary brain tumors, with glioblastoma (GB) carrying a median overall survival of less than 15 months despite surgery, radiotherapy, and chemotherapy. Although somatic alterations in isocitrate dehydrogenase ( IDH1/2 ), the TERT promoter, and 1p/19q chromosomal codeletion now define the 2021 WHO Classification of CNS Tumors, single nucleotide polymorphisms (SNPs) form a distinct biological layer that clinical practice has so far largely ignored. Genome-wide association studies (GWAS) have now confirmed 26 risk loci for glioma, collectively accounting for approximately 27% of the familial risk of GB and 37% of the familial risk of non-GB tumors. This review covers the full landscape of glioma-associated SNPs across all WHO grades and molecular subtypes, examines gene–environment interactions and pharmacogenomic implications, and discusses how germline SNP genotypes serve as an analytical reference for cerebrospinal fluid (CSF) liquid biopsy, in which tumor-derived somatic alterations are detected and quantified. We also address key gaps: the near-exclusive use of European-ancestry cohorts in GWAS, the lack of functional validation for most risk variants, and the path toward polygenic risk score (PRS) in neuro-oncology. Combining multi-omic data with AI is the most direct path to making SNP panels clinically useful.

Authors

Institutions

Publication Details

Journal
Frontiers in Molecular Medicine
Published
2026-11-19
DOI
https://doi.org/10.3389/fmmed.2026.2013984
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Single nucleotide polymorphisms in glioma: from susceptibility loci to pharmacogenomic biomarkers

Н. В. Губанова, Григорьева Эльвира Витальевна
Frontiers in Molecular Medicine
Glioma Diagnosis and Treatment
article

Single nucleotide polymorphisms in glioma: from susceptibility loci to pharmacogenomic biomarkers

Н. В. Губанова, Григорьева Эльвира Витальевна
article en

Abstract

Gliomas are among the deadliest primary brain tumors, with glioblastoma (GB) carrying a median overall survival of less than 15 months despite surgery, radiotherapy, and chemotherapy. Although somatic alterations in isocitrate dehydrogenase ( IDH1/2 ), the TERT promoter, and 1p/19q chromosomal codeletion now define the 2021 WHO Classification of CNS Tumors, single nucleotide polymorphisms (SNPs) form a distinct biological layer that clinical practice has so far largely ignored. Genome-wide association studies (GWAS) have now confirmed 26 risk loci for glioma, collectively accounting for approximately 27% of the familial risk of GB and 37% of the familial risk of non-GB tumors. This review covers the full landscape of glioma-associated SNPs across all WHO grades and molecular subtypes, examines gene–environment interactions and pharmacogenomic implications, and discusses how germline SNP genotypes serve as an analytical reference for cerebrospinal fluid (CSF) liquid biopsy, in which tumor-derived somatic alterations are detected and quantified. We also address key gaps: the near-exclusive use of European-ancestry cohorts in GWAS, the lack of functional validation for most risk variants, and the path toward polygenic risk score (PRS) in neuro-oncology. Combining multi-omic data with AI is the most direct path to making SNP panels clinically useful.

Frontiers in Molecular MedicineVol. 6
Sirius University of Science and Technology (RU), Institute of Molecular Biology and Biophysics (RU)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon